The capital is pricing NMN as a NAD+ precursor with consumer supplement margins and a pathway to regulated nutraceutical status across ASEAN. The clinical ledger, as of the most recently registered Phase 2 trial (NCT04823260, 60 participants, primary endpoint: NAD+ tissue concentration measured by 31P-MRS, 12-week duration), shows measurable NAD+ repletion in circulating blood but no demonstrated effect on the endpoints that family-office health portfolios are actually pricing: muscle function by SPPB score, cognitive composite, or all-cause mortality proxy. The gap between "NAD+ goes up" and "patient outcomes improve" is not a rounding error. It is the entire clinical question.

Singapore's Health Sciences Authority placed NMN under prescription-only classification in November 2023, a move that positioned MOH's Pharmacy Regulation Division ahead of both TGA's Complementary Medicines branch, which still permits OTC sale pending a post-market review scheduled for Q3 2026, and NMPA's Center for Drug Evaluation, which has accepted IND filings for NMN analogs under the traditional medicine-new drug hybrid pathway since early 2024. The regulatory divergence is creating a three-speed APAC market: Singapore as prescription floor, China as hybrid-drug accelerant, Australia as the OTC channel that funds the marketing. What is being priced across the region is not a proven mechanism -- it is regulatory arbitrage between three agencies that have not yet aligned on what category of product NMN actually is, and the Q3 2026 TGA post-market determination will either close the Australian retail window or widen it before any Phase 3 efficacy data exists.